EMMA
vs
S&P 500
EMMA
S&P 500
Over the past 12 months, EMMA has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's +19% growth.
Stocks Performance
EMMA vs S&P 500
Performance Gap
EMMA vs S&P 500
Performance By Year
EMMA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Emmaus Life Sciences Inc
Glance View
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.